Lei Yang, PhD
Associate Research ScientistCards
About
Research
Publications
2025
rtmsEcho: An Open-Source R Package for Automated Analysis of Acoustic Ejection Mass Spectrometry Data
Rimmer M, Twarog N, Ranathunge T, Wang J, Li Y, Chen T, Shelat A, Yang L. rtmsEcho: An Open-Source R Package for Automated Analysis of Acoustic Ejection Mass Spectrometry Data. Analytical Chemistry 2025, 97: 20444-20452. PMID: 40940023, PMCID: PMC12462762, DOI: 10.1021/acs.analchem.5c03730.Peer-Reviewed Original ResearchConceptsAcoustic Ejection Mass SpectrometryMass spectrometryAnalysis of complex samplesLC-MS systemFull-scan acquisitionQuantitative analysis of complex samplesChromatographic separationHigh-throughput workflowComplex samplesLC-MSDrug discoverySpectrometryTargeted analysisClinical diagnosticsQuantitative analysisHigh-throughput applicationsSpectral analysisMRMPeak detectionSeparationChromatographyReproducibilityUnbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics
Steger M, Nishiguchi G, Wu Q, Schwalb B, Shashikadze B, McGowan K, Actis M, Aggarwal A, Shi Z, Price J, Mayasundari A, Yang L, Bednarz A, Machata S, Graef T, Bartoschek D, Demichev V, Ohmayer U, Yang J, Daub H, Rankovic Z. Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics. Nature Communications 2025, 16: 7773. PMID: 40835825, PMCID: PMC12368047, DOI: 10.1038/s41467-025-62829-0.Peer-Reviewed Original ResearchConceptsMolecular glue degradersHigh-throughput proteomic platformsData-independent acquisition mass spectrometryDIA-MSMass spectrometryHigh-throughput proteomicsSmall moleculesDrug discoveryGlue degradersRelationship analysisLabel-freeScreening approachTarget proteinsPhenylNovel degradersImideDegradation of target proteinsProteomics platformUbiquitin-proteasome systemNeosubstratesLigandDegradationSpectrometryMoleculesProteome-wide screening approachDecoding the selective chemical modulation of CYP3A4
Wang J, Nithianantham S, Chai S, Jung Y, Yang L, Ong H, Li Y, Zhang Y, Miller D, Chen T. Decoding the selective chemical modulation of CYP3A4. Nature Communications 2025, 16: 3423. PMID: 40210880, PMCID: PMC11985932, DOI: 10.1038/s41467-025-58749-8.Peer-Reviewed Original ResearchConceptsDesign of compoundsModulation of CYP3A4High-throughput screeningCytochrome P450Structure-guided designMarketed drugsLigand-binding surfaceLoop conformationInhibit CYP3A4Chemical modulatorsSelective inhibitorsCYP3A4 inhibitorsLigandCYP3A4Binding surfaceConformationComputational analysisCompoundsScaffolds
2024
Development of Brain Penetrant Pyridazine Pantothenate Kinase Activators
Tangallapally R, Subramanian C, Yun M, Edwards A, Sharma L, Yang L, Creed K, Wang J, Jackowski S, Rock C, White S, Lee R. Development of Brain Penetrant Pyridazine Pantothenate Kinase Activators. Journal Of Medicinal Chemistry 2024, 67: 14432-14442. PMID: 39136313, PMCID: PMC11345825, DOI: 10.1021/acs.jmedchem.4c01211.Peer-Reviewed Original ResearchConceptsCoA levelsAcyl-CoA levelsIncreased CoA levelsBiosynthesis pathwayPantothenate kinaseStructure-guided designCoA biosynthesisPropionic acidemiaCoenzyme APantothenate kinase-associated neurodegenerationSmall molecule activationCultured cellsBiosynthesisMolecule activationStructure-activity relationshipEnzymeActivation potentialPharmacokinetic profilePhosphopantothenateClinical testingPanKCoAKinaseMetabolic stabilityIsoformsExploring the Molecular Mechanism of Comorbidity of Type 2 Diabetes Mellitus and Colorectal Cancer: Insights from Bulk Omics and Single-Cell Sequencing Validation
Luo Y, Yang L, Wu H, Xu H, Peng J, Wang Y, Zhou F. Exploring the Molecular Mechanism of Comorbidity of Type 2 Diabetes Mellitus and Colorectal Cancer: Insights from Bulk Omics and Single-Cell Sequencing Validation. Biomolecules 2024, 14: 693. PMID: 38927096, PMCID: PMC11201668, DOI: 10.3390/biom14060693.Peer-Reviewed Original ResearchConceptsComorbid genesMolecular mechanismsCancer-associated fibroblastsSingle-cell RNA-seq dataRNA-seq dataType 2 diabetes mellitusColorectal cancerSingle-cell analysisSingle-cell levelRNA-seqGene regulationIntrinsic molecular featuresAssociated with immune responseSequencing validationImmune biomarkersCrosstalk mechanismGenesComorbidity of type 2 diabetes mellitusTumor-suppressive featuresColorectal cancer patientsEVPLPotential drugsConnectivity mapsImmunotherapy biomarkersMolecular featuresComparative analysis of first-line therapy with fruquintinib plus chemotherapy versus standard therapy in advanced metastatic colorectal cancer (mCRC): A prospective cohort study compared with propensity score matching (PSM) cohort.
Zhou F, Wen-bo W, Xia L, Dai J, Wu H, Yang L, Gong J, Chen X, Xiong Z, Liang X. Comparative analysis of first-line therapy with fruquintinib plus chemotherapy versus standard therapy in advanced metastatic colorectal cancer (mCRC): A prospective cohort study compared with propensity score matching (PSM) cohort. Journal Of Clinical Oncology 2024, 42: 3591-3591. DOI: 10.1200/jco.2024.42.16_suppl.3591.Peer-Reviewed Original ResearchMetastatic colorectal cancerFirst-line therapyPropensity score matchingSafety profileStandard therapySingle-arm phase 2 studyAdvanced metastatic colorectal cancerDuration of treatment exposureMCRC ptsNon-operative therapyPhase 2 studyFirst-line treatmentProspective cohort studyFollow-up dataClinically relevant variablesCapecitabine maintenanceFavorable PFSMedian PFSPlus chemotherapyDurable responsesMCRC patientsCombination regimensOpen-labelNo significant differenceBRAF mutationsHistologic transformation of rectal adenocarcinoma to choriocarcinoma after surgery and chemotherapy: A rare case report and review of the literature
Zhong J, Yang L. Histologic transformation of rectal adenocarcinoma to choriocarcinoma after surgery and chemotherapy: A rare case report and review of the literature. International Journal Of Surgery Case Reports 2024, 117: 109478. PMID: 38458023, PMCID: PMC10943425, DOI: 10.1016/j.ijscr.2024.109478.Peer-Reviewed Original ResearchAbdominopelvic resectionRectal adenocarcinomaNext-generation sequencingB-hCG levelsPostoperative pathological findingsPrimary rectal adenocarcinomaRare case reportDiagnosis of adenocarcinomaLow rectal cancerPatient died 8Post-operative recurrenceImprove patient prognosisHistological transformationChemotherapy regimensAdenocarcinoma componentSecondary biopsyTumor biopsiesRectal cancerPathology reportsPregnancy-relatedClinical outcomesImaging findingsCase reportChoriocarcinomaRare case
2023
612P Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
Zhou F, Wang W, Xia L, Dai J, Wu H, Yang L, Gong J, Chen X, Xiong Z, Liang X. 612P Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC). Annals Of Oncology 2023, 34: s439. DOI: 10.1016/j.annonc.2023.09.1803.Peer-Reviewed Original ResearchThe role of image-guided volume-adapted high-dose-rate endorectal brachytherapy boost in total neoadjuvant treatment of distal locally advanced rectal cancer.
Jiang H, Dai J, Wen-bo W, Xia L, Yang L, Peng J, Xu H, Wu H, Wang Y, Wang Q, Wei Y, Jiang C, Xiong B, Zhou F. The role of image-guided volume-adapted high-dose-rate endorectal brachytherapy boost in total neoadjuvant treatment of distal locally advanced rectal cancer. Journal Of Clinical Oncology 2023, 41: 3611-3611. DOI: 10.1200/jco.2023.41.16_suppl.3611.Peer-Reviewed Original ResearchLocally Advanced Rectal CancerClinical complete responsePathological complete responseAdvanced rectal cancerMedian Wexner fecal incontinence scoreSustained clinical complete responseRadiation Therapy Oncology GroupCircumferential resection marginHigh-dose-rateRectal cancerMagnetic resonance imagingEndorectal brachytherapyComplete responseNeoadjuvant treatmentRadiation proctitisClinical stage II-IIIPositive circumferential resection marginWatch-and-wait strategyPathological regression rateTotal neoadjuvant treatmentComplete response ratePathologic tumor responseClinical stage IIR0 resection rateDisease-free survivalMobile-based multimodal rehabilitation including exercise, nutritional, and psychological interventions in patients with abdominal cancer receiving concurrent chemoradiotherapy: Prospective, multicenter, randomized trial.
Yang L, Wen-bo W, Xiong Y, Cao D, Dai J, Xu H, Wu H, Peng J, Wang Y, Su J, Chen X, Wang Q, Jiang H, Xia L, Chen W, Xu X, Zhou F. Mobile-based multimodal rehabilitation including exercise, nutritional, and psychological interventions in patients with abdominal cancer receiving concurrent chemoradiotherapy: Prospective, multicenter, randomized trial. Journal Of Clinical Oncology 2023, 41: e24138-e24138. DOI: 10.1200/jco.2023.41.16_suppl.e24138.Peer-Reviewed Original ResearchMultimodal rehabilitationGrip strengthPsychological interventionsGrip strength of patientsAbdominal cancer patientsStrength of patientsNutritional statusGrip strength lossControl groupTeam of oncologistsStudy groupCancer patientsExercise programNutritional status of patientsRehabilitation physiciansOncology careMobile healthStatus of patientsTreatment completion ratesClinical nutritionistsRehabilitationCompletion ratesAverage weight lossTolerance of patientsExercise